Daniel C Berwick
Overview
Explore the profile of Daniel C Berwick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
734
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bailey A, Berwick D, Camarini R, Scavone C
Br J Pharmacol
. 2022 Mar;
179(8):1475-1477.
PMID: 35292961
No abstract available.
2.
Azeggagh S, Berwick D
Br J Pharmacol
. 2021 May;
179(8):1478-1495.
PMID: 34050929
Current therapeutic approaches for Parkinson's disease (PD) are based around treatments that alleviate symptoms but do not slow or prevent disease progression. As such, alternative strategies are needed. A promising...
3.
Berwick D, Heaton G, Azeggagh S, Harvey K
Mol Neurodegener
. 2019 Dec;
14(1):49.
PMID: 31864390
Since the discovery of leucine-rich repeat kinase 2 (LRRK2) as a protein that is likely central to the aetiology of Parkinson's disease, a considerable amount of work has gone into...
4.
Granno S, Nixon-Abell J, Berwick D, Tosh J, Heaton G, Almudimeegh S, et al.
Sci Rep
. 2019 May;
9(1):7322.
PMID: 31086297
Pathological mechanisms underlying Down syndrome (DS)/Trisomy 21, including dysregulation of essential signalling processes remain poorly understood. Combining bioinformatics with RNA and protein analysis, we identified downregulation of the Wnt/β-catenin pathway...
5.
Berwick D, Javaheri B, Wetzel A, Hopkinson M, Nixon-Abell J, Granno S, et al.
Mol Neurodegener
. 2017 Jan;
12(1):9.
PMID: 28103901
Background: LRRK2 mutations and risk variants increase susceptibility to inherited and idiopathic Parkinson's disease, while recent studies have identified potential protective variants. This, and the fact that LRRK2 mutation carriers...
6.
Nixon-Abell J, Berwick D, Harvey K
Biochem Soc Trans
. 2016 Dec;
44(6):1625-1634.
PMID: 27913671
Leucine-rich repeat kinase 2 (LRRK2) is a central protein in the pathogenesis of Parkinson's disease (PD), yet its normal function has proved stubbornly hard to elucidate. Even though it remains...
7.
Nixon-Abell J, Berwick D, Granno S, Spain V, Blackstone C, Harvey K
Front Mol Neurosci
. 2016 Mar;
9:18.
PMID: 27013965
Mutations in LRRK2 are a common cause of familial and idiopathic Parkinson's disease (PD). Recently, the LRRK2 GTPase domain R1398H variant was suggested in genetic studies to confer protection against...
8.
Law B, Spain V, Leinster V, Chia R, Beilina A, Cho H, et al.
J Biol Chem
. 2013 Nov;
289(2):895-908.
PMID: 24275654
Mutations in LRRK2, encoding the multifunctional protein leucine-rich repeat kinase 2 (LRRK2), are a common cause of Parkinson disease. LRRK2 has been suggested to influence the cytoskeleton as LRRK2 mutants...
9.
Berwick D, Harvey K
J Mol Cell Biol
. 2013 Oct;
6(1):3-12.
PMID: 24115276
Wingless/Int (Wnt) signaling pathways are signal transduction mechanisms that have been widely studied in the field of embryogenesis. Recent work has established a critical role for these pathways in brain...
10.
Berwick D, Harvey K
Front Cell Neurosci
. 2013 Jun;
7:82.
PMID: 23754980
The importance of leucine-rich repeat kinase 2 (LRRK2) to mature neurons is well-established, since mutations in PARK8, the gene encoding LRRK2, are the most common known cause of Parkinson's disease....